嘉南藥理科技大學專題研究計畫成果報告

心臟型脂肪酸結合蛋白單株及多株抗體之生產

計畫類別：V 個別型計畫　　□整合型計畫

計畫編號：CNBT93-15

執行期間：93 年 1 月 1 日至 93 年 12 月 31 日

計畫主持人：周淑芬

共同主持人：

計畫參與人員：謝東文、余欣嶸

執行單位：生物科技系

中華民國　94　年　2　月　1　日

Production and Purification of New Monoclonal and Polyclonal Antibodies Against Heart-type Fatty Acid-Binding Protein (HFABP)

Shu-Fen Chou

Department of Biotechnology, Chia-Nan University of Pharmacy and Science, Tainan, Taiwan, R.O.C.

Abstract

The aim of this study was to produce monoclonal and polyclonal antibodies against heart-type fatty acid-binding protein (HFABP). Hyperimmune ICR mice produced polyclonal antibodies after injection with 0.5 mL pristane, and were injected with NS-1 myeloma cells two weeks later. Hyperimmune Balb/c mice were used for the production of monoclonal antibodies (MAbs). After these mice were immunized four times and given a final boost, their spleen cells were collected and fused with NS-1 myeloma cells under the presence of PEG 1500. The fused cells were then selected in the hypoxathine, aminopterine, and thymidine (HAT)-RPMIX medium. Anti- HFABP antibody-secreting hybridoma cell lines with high titer were cloned by enzyme-linked immunosorbent assay **(**ELISA) and then subcloned by limiting dilution in 15% fetal bovine serum (FBS) HT-RPMIX medium. Nine murine hybridoma producing anti- HFABP MAbs were obtained and designated HB1, HC2, HE4, HB9, HA2, HC7, HD6, HD11, and HE5. Isotypes of these MAbs were identified as IgG2a heavy chain and κ light chain. Hitrap Protein A column was used for the purification of polyclonal and monoclonal antibodies.

1. Introduction

Ischaemic heart disease is the most common health problem in the industrialized world. Acute myocardial infarction (AMI) is the major single cause of cardiovascular morbidity and mortality. Because only early treatment, such as administration of thrombolytic therapy, improves survival of cardiac muscle, rapid differentiation of patients with and those without AMI is important. However, in only a minority of patients with chest pain who are admitted to emergency rooms, initial evaluation (medical history, physical examination and electrocardiogram), is conclusive [1,2]. In order to risk-stratify non-conclusive patients, the use of cardiac markers has become a standard procedure [3-5].

Commonly used cardiac markers are creatine kinase-MB (CK-MB), cardiac troponins I or T (cTnI and cTnT, respectively), and myoglobin [5-8]. Recently, 14.5-kDa cytoplasmic HFABP was introduced as an early marker for myocardial injury [9-12]. Due to its abundant occurrence in heart muscle combined with its relatively low plasma reference concentration [13,14], HFABP plasma concentrations are significantly increased above the upper reference level (URL) within 2-3h after cardiac injury. In addition, HFABP appears to be more specific and more sensitive than myoglobin [15].

The aim of this study was to produce new anti-HFABP antibodies including polyclonal and monoclonal antibodies for application in the development of AMI immunosensors. In this study, new polyclonal and monoclonal anti-HFABP antibodies were produced, characterized, and purified.

2. Materials and Methods

2.1 Reagents

1. HFABP from human heart tissue (Biodesign International, Saco, ME, U.S.A) 2. RPMIX: RPMI 1640 (Seromed, Berlin, Germany) was supplemented with fetal bovine serum (FBS) (Hyclone, Logan, Utah, U.S.A.) 12%, L-glutamine (200 mM, GibcoBRL, Grand island, NY, U.S.A.) 1%, Pen-Strep (10000 U penicillin G and 10 mg streptomycin/mL solution, 100X, GibcoBRL, Grand island, NY, U.S.A.) 1%, fungizon (250 μg/mL, GibcoBRL, Grand island, NY, U.S.A.) 1% and sodium pyruvate (100 mM, GibcoBRL, Grand island, NY, U.S.A.) 1%. 3. Fruend's adjuvant (complete and incomplete, GibcoBRL, Grand island, NY, U.S.A.) 4. Peroxidase conjugated goat anti-mouse IgA, IgG, IgM (Capple, Malvern, PA, U.S.A.) 5. ABTS (2,2-azino-di- [3-ethyl-benzthiazoline sulfonate] diammonium salt) (Sigma, St. Louis, MO, U.S.A.) 6. PEG1500 (polyethylene glycol 1500) (Roche Diagnostics GmbH, Mannheim, Germany) 7. HAT (hypoxanthine 10 mM, thymidine 1.6 mM, aminopterin 1.76 mg/100mL) (GibcoBRL, Grand island, NY, U.S.A.) 8. HT (hypoxanthine 10 mM, thymidine 1.6 mM) (GibcoBRL, Grand island, NY, U.S.A.) 9. Hitrap rProtein A column (Amersham Pharmacia Biotech, Inc., Piscataway, NJ. U.S.A.)

2.2 Materials

The NS-1 myeloma cell line was a gift from Dr. Rong Huay Juang in the Agriculture Chemistry Department of Taiwan University, Taiwan, R.O.C.. Balb/c mice and ICR mice (six to eight weeks old, male) were obtained from the Experimental Animal Center of the Medical College of National Taiwan University, R.O.C..

2.3 Immunization

All Balb/c and ICR mice were given an initial intraperitoneal (i.p.) immunization with 10 μg purified antigen in complete Freund's adjuvant (Gibco, Grand island, NY) and then boosted the antigen in incomplete Freund's adjuvant (Gibco) at 3-week intervals. After three months, the ICR mice could produce ascites and the spleens from the Balb/c mice were used in the production of hybridoma cells [16,17].

2.4 Procedure of Enzyme-linked immunosorbent assay (ELISA)

Fifty micrograms per milliliter of antigen (HFABP) was adsorbed into a 96-well microtiter plate at 4℃ overnight. After coating, the plate was washed twice with phosphate buffered saline (PBS) (5 mM phosphate buffer, 0.15 M NaCl, pH 7.0). 0.2 ml of gelatin-NET solution (gelatin 0.5%, NaCl 0.15 M, EDTA • 2Na 5 mM. Tween 20 0.05%, Tris base 50 mM, pH 8.0) was then added to the plate for blocking at room temperature. After 1 hr, the plate was washed twice with PBST (NaH_2PO_4 • $2H_2O$ 10 mM, NaCl 0.13 M, Tween 20 0.05%, pH 7.0). 0.1 mL of antibody solution was added to the wells and incubated at 37℃ for 30 min, then 4℃ for 30 min. After antibody-antigen reaction, the plate was washed three times with PBST and 0.1 mL of peroxidase conjugated goat anti-mouse antibody was added to the wells and incubated at 37℃ for 30 min, then at 4℃ for 30 min. After 1 hr of incubation with these antibodies, the plate was washed three times with PBST and the enzyme substrate, H_2O_2 and ABTS was added. Absorbance at 405 nm of the colored reaction product was measured by an automated ELISA reader (MR5000, Dynatech) [16,17].

2.5 Production of Polyclonal Antibodies

The hyperimmunized ICR mice were injected with 0.5 mL pristane (2,6,10,14-tetramethyldecanoic acid). Two weeks later, the mice were injected with 10^6 NS-1 cells. The fluid was tapped when the mice were noticeably enlarged, but before the mice had difficulty moving. After centrifugation at 3000 × g for 10 min, supernatant was carefully removed and the oil layer discarded [17].

2.6 Production of Monoclonal Antibodies (MAbs)

2.6.1 Hybridization

Seven days before fusion, a hyperimmunized mouse was given a final boost of 10 μg antigen in PBS (pH 7.0) at least three weeks after the previous injection. The spleen was then removed and spleen cells (10^8) fused with NS-1 myeloma cells (10^7) using PEG 1500. Fused cells were selected in the hypoxathine, aminopterine, and thymidine (HAT)-RPMIX medium. Anti- HFABP antibody-secreting hybridoma cell lines with high titer were cloned by ELISA and then subcloned by limiting dilution in 15% FBS HT-RPMIX medium [16,17].

2.6.2 Scale-up of MAbs Production

The production of MAbs was scaled up by tissue culture in flasks and ascitic fluid in mice.

2.6.2.1 Collection of tissue culture supernatants

The cultures were allowed to grow until the hybridomas died, and the tissue culture supernatants were collected. Debris was removed by centrifugation (1000 × g, 10 min) and supernatants were decanted from the cell pellet [16,17]. Supernatant titers were determined by ELISA.

2.6.2.2 Collection of ascites

Prime Balb/c mice were injected i.p. with 0.5 mL of pristane or incomplete Freund's adjuvant. After 7-14 days, the mice were injected i.p. with $5 \times 10^5 \sim 5 \times 10^6$ hybridoma cells in 0.5 mL PBS. Ascitic fluid began to build up within 1-2 weeks and was tapped when the mouse was noticeably enlarged, but before the mouse had difficulty moving. The fluid was incubated at 37℃ for 1 hr and maintained at 4℃ overnight. After centrifugation at 3000 × g, 10 min, supernatant was carefully removed and the oil layer discarded [16,17].

2.7 Classification of MAbs

Monoclonal cell culture supernatant (0.1 mL) was added to the ELISA plate that had adsorbed the antigen. After 1 hr of incubation at room temperature, the plate was washed three times with PBST. Eight kinds of isotype goat anti-mouse Ig-peroxidase conjugates were then added to the plate for 1 hr of incubation. The plate was washed three times with PBST and absorbance at 405 nm was measured.

2.8 Purification of Polyclonal and Monoclonal Antibodies Using Hitrap rProtein A column

The sample was pretreated by the ammonium sulfate precipitation. The Hitrap rProtein A column was equilibrated with at least two column volumes of binding buffer (Buffer A) (20 mM sodium phosphate, pH 7.0). It was then applied to the sample by pumping it into the column, which was washed with Buffer A for 10 column volumes or until no material appeared in the effluent. It was eluted with elution buffer (Buffer B) (0.1 M citric acid buffer, pH 5.0) 1-3 column volumes. The purified IgG fraction could be desalted by dialysis. Flow rates of washing and equilibration were 4 mL/min, and rates of sample application and elution were 2 mL/min.

3. Results

3.1 Production and Purification of Polyclonal Antibodies

Ascites formation could be induced in hyperimmune ICR mice (serum titer $1:10^4$) when injected with pristane and then NS-1 myeloma cells after two weeks. The highest dilution fold of the ascites determined by ELISA was 15625-fold. The ascites were purified using Hitrap rProtein A column. A single peak of protein fraction (OD_{280nm}=3.8) was obtained when Buffer B was applied to the column (data not shown).

3.2 Production and Classification of MAbs

In this experiment, the nine high-titer MAbs-producing hybridoma cell lines selected and designated HB1, HC2, HE4, HB9, HA2, HC7, HD6, HD11, and HE5 are shown in Fig. 1. The isotypes of MAbs secreted by the twelve hybridoma cell lines were classified as IgG2a heavy chain and κ light chain using mouse-hybridoma subtyping kit. When high-titer hybridoma was injected i.p. into mice, a tumor formed locally or antibody-rich ascites developed. The titer curve of mouse anti-HFABP ascites produced with hybridoma cell line HB1 is shown in Fig. 2. The highest dilution fold of the hybridoma ascites determined by ELISA was 15625-fold.

3.3 Purification of MAbs

The ascites containing anti- HFABP MAbs HB1 was purified using Hitrap rProtein A column. An affinity chromatogram of anti- HFABP MAbs HB1 from Balb/c mice ascites using Hitrap rProtein A purification column is shown in Fig. 3. A single peak of protein fraction (OD_{280nm}=3.5) was obtained when elution buffer (Buffer B) was applied to the column.

4. Discussion

HFABP is a kind of complete antigens. This antigen mixed with Freund's adjuvant can stimulate a good response when injected into mice. A successful fusion procedure could bring cells together with an optimal frequency of interactions between the two "parent" cell types. Unfused myeloma cells were dying out as a result of the aminopterin block. Spleen cells were dying out, with the exception of macrophages and/or fibroblasts, which might be establishing themselves, and beginning to divide [(11)]. It appeared to be a correlation between the appearance of such cells and subsequent good yields of hybrids. The cells were characteristically round with a clear membrane under phase contrast. When the medium in the culture turned yellow, the cultures were screened to determine antibody production and positive colonies by ELISA were selected for expansion and subcloning. In this study, limiting dilution was performed by adding 15% FBS HT-RPMIX medium to replace the conventional method that used feeder cells applied for hybridoma cells in the 96-well microtiter plate. Maintenance and expansion of MAbs- producing hybridoma cell lines were important. The class and subclass should be determined on MAb prepared in culture, rather than in mice, to avoid other classes and subclasses, originating from the mouse model.

References

1. Katz, I. A., Irwig, L., Vinen, J. D., March, L., Wyndham, L. E., Luu, T., et al. 1998. Biochemical markers of acute myocardial infarction: strategies for improving their clinical usefulness, Ann. Clin. Biochem. 35, 393-399.
2. Newby, L. K., Storrow, A. B., Gibler, W. B., Garvey, J. L., Tucker, J. F., Kaplan, A. L., et al. 2001. Beside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study, Circulation 103, 1832-1837.
3. Hamm, C. W., 1994. New serum markers for acute myocardial infarction, New Engl. J. Med. 331, 607-608.
4. Hamm, C. W., Katus, H. A., 1995. New biochemical markers for myocardial cell injury, Curr. Opin. Cardiol. 10, 355-360.
5. Haider, K. H., Stimson, W. H., 1999. Cardiac myofibrillar proteins: biochemical markers to estimate myocardial injury, Mol. Cell. Biochem. 194, 31-39.
6. McComb, J. M., McMaster, E. A., Jadgey, A. A., 1985. Myoglobin in the very early phase of acute myocardial infarction, Ann. Clin. Biochem. 22, 152-155.
7. Mair, J., 1997. Progress in myocardial damage detection: new biochemical markers for clinicians, Crit. Rev. Clin. Lab. Sci. 34, 1-66.
8. Mair, J., Morandell, D., Genser, N., Lechleitner, P., Doenstl, F., Puschendorf, B., 1995. Equivalent early sensitive of myoglobin, creatine kinase MB mass, creatine kinase isoform ratios, and cardiac troponins I and T for acute myocardial infarction, Clin.Chem. 41, 1266-1272.
9. Kieine, A. H., Glatz, J. F., Van Nieuwenhoven, F. A., Van der Vusse, G. J., 1992. Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man, Mol. Cell. Biochem. 116, 155-162.
10. Ishii, J., Wang, J. H., Naruse, H., Taga, S., Kinoshita, M., Kurokawa, H., et al. 1997. Serum concentrations of myoglobin vs.

human heart-type cytoplasmic fatty acid-binding protein in early detection of acute myocardial infarction, Clin.Chem. 43, 1372-1378.
11. Hermens, W. T., Pelsers, M. M., Mullers-Boumans, M. L., de Zwaan, C., Glatz, J. F., 1998. Combined use of markers of muscle necrosis and fibrinogen conversion in the early differentiation of myocardial infarction and unstable angina, Clin.Chem. 44, 890-892.
12. van der Laarse, A., 1999. Rapid estimation of myocardial infarct size, Cardiovasc. Res. 44, 247-248.
13. Kragten, J. A., van Nieuwenhoven, F. A., van Dieijen-Visser, M. P., Theunissen, P. H., Hermens, W. T., Glatz, J. F., 1996. Distribution of myoglobin and fatty acid-binding protein in human cardiac autopsies, Clin.Chem. 42, 337-338.
14. Pelsers, M. M., Chapelle, J. P., Knapen, M., Vermeer, C., Muijtjens, A. M., Hermens, W. T., et al. 1999. Influence of age and sex and day-to-day and within-day biological variation on plasma concentrations of fatty acid-binding protein and myoglobin in healthy subjects, Clin.Chem. 45, 441-443.
15. van Nieuwenhoven, F. A., Kieine, A. H., Wodzig, W. H., Hermens, W. T., Kragten, H. A., Maessen, J. G., et al. 1995. Discrimination between myocardial and skeletal muscle injury by assessment of the plasma ratio of myoglobin over fatty acid-binding protein, Circulation 92, 2848-2854.
16. Hurrell, J. G. R., Monoclonal hybridoma antibodies: Techniques and Application, CRC press, Inc., Florida, U.S.A.,1982.
17. Chuang, Z. H., Studies on sucrose synthetase from rice, Doctor Thesis of the Graduated Institute of Agriculture Chemistry in National Taiwan University, Taipei, Taiwan, 1985.

Figure legends:

Fig.1. Selection for anti- HFABP MAb-secreting hybridoma cell lines with high titer

Fig.2. Titer curve of anti- HFABP ascites produced by i.p. injection of mice with hybridoma cells HB1. The Balb/c mice were injected 0.5 mL pristane. After 7-14 days, the mice were injected i.p. with 10^5-10^6 hybridoma cells in 0.5 mL PBS. The ascitic fluid built up within 1-2 weeks following the injection of the cells.

Fig.3. Affinity chromatogram of Balb/c mice ascites producing monoclonal anti-HFABP antibodies HB1 using Hitrap rProtein A purification column. 10 mL of the hybridoma ascites was applied into the column. The binding buffer (Buffer A) is a solution containing 0.05 M Tris-HCl, 3 M NaCl (pH 7.8). The elution buffer (Buffer B) is a 0.1 M citrate buffer (pH 5.0). Flow rate of washing and equilibration is 4 mL/min. Flow rate of sample application and elution is 1 mL/min (1 mL/fraction).


Hybridoma cell line
HE5
HD11
HD6
HC7
HA2
HB9
HE4
HC2
HB1
0.0
0.5
1.0
1.5
2.0
2.5
A405

Fig.1


5
4
3
2
1
0
A405
-14
-12
-10
-8
-6
-4
-2
0
Dilution fold of ascites (log5)

Fig.2



Fig.3